Detalles de la búsqueda
1.
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001).
J Allergy Clin Immunol
; 153(4): 1040-1049.e12, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38157942
2.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Lancet
; 402(10412): 1541-1551, 2023 10 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738999
3.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33891380
4.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
N Engl J Med
; 385(24): 2219-2229, 2021 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34879448
5.
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
Rheumatology (Oxford)
; 2024 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38341669
6.
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
J Am Acad Dermatol
; 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38447700
7.
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry.
J Am Acad Dermatol
; 90(1): 82-90, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37739267
8.
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
J Am Acad Dermatol
; 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38588819
9.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
J Am Acad Dermatol
; 90(4): 775-782, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38122848
10.
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
J Am Acad Dermatol
; 90(3): 494-503, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37951245
11.
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
J Eur Acad Dermatol Venereol
; 38(5): 864-872, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38179809
12.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38451052
13.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Br J Dermatol
; 188(1): 22-31, 2023 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689515
14.
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Br J Dermatol
; 188(3): 330-340, 2023 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36751950
15.
Bimekizumab maintenance of response through 3â years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Br J Dermatol
; 188(6): 749-759, 2023 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36967713
16.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol
; 89(3): 486-495, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37182701
17.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115523
18.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
J Am Acad Dermatol
; 88(1): 29-39, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35820547
19.
Pharmacology of orismilast, a potent and selective PDE4 inhibitor.
J Eur Acad Dermatol Venereol
; 37(4): 721-729, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36527389
20.
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.
J Eur Acad Dermatol Venereol
; 37(4): 711-720, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36478476